DRL generates primary cells directly from fresh patient tumors — key difference from immortalized lines that have drifted away from actual tumor biology after years in culture. Every primary cell model we build is isolated at low passage, preserving biological fidelity that functional assays depend on. This is the difference between testing your drug on human biology and testing it on a cell population that no longer reflects a real patient.

Yes. DRL provides both banked inventory and prospective procurement — consented, protocol-driven collection of fresh frozen or formalin fixed, paraffin embedded (FFPE) tissue, blood products, PBMCs, and selected biofluids. Every sample ships with relevant clinical metadata. Availability depends on indication and collection feasibility; contact our team to confirm for your specific needs.

Yes. Through our network of 33 hospitals and 18 clinics, DRL procures fresh tumor tissue within 24 hours of surgery, with full chain-of-custody documentation and linked clinical context. This is prospective procurement — built around your protocol, not pulled from a bank.

Yes. Through the GLP-aligned Bio-Verify platform, DRL runs drug screening, functional assays, molecular profiling, and biomarker discovery and validation — all on human-derived primary cells or organoids. Studies are structured for IND-enabling documentation and decision-grade R&D.

DRL generates primary cells directly from fresh patient tumors — key difference from immortalized lines that have drifted away from actual tumor biology after years in culture. Every primary cell model we build is isolated at low passage, preserving biological fidelity that functional assays depend on. This is the difference between testing your drug on human biology and testing it on a cell population that no longer reflects a real patient.

It depends on your endpoints. Programs that need clinically linked material for discovery typically start with prospective biospecimens. Programs running functional assays or drug screening often move directly to primary cells or 3D organoids. DRL will recommend the right starting point based on your indication, target, and timeline — reach out and we will map a path.

Yes, where feasible. DRL can co-isolate stromal and CAF components, provide tumor immune cell fractions (including CD45+), and build immune co-culture models for TME and IO hypothesis testing. Study scope depends on tissue availability and design; our team will confirm feasibility upfront.

DRL connects fresh tissue procurement → primary model generation → GLP-aligned validation assays under one strategy, one data backbone, and one point of contact. Fewer handoffs means fewer delays — and tighter QC at every step. This is the full-stack integration that fragmented vendor models cannot deliver.

Prospective biospecimen procurement means samples are collected to a defined research protocol after patient consent — not pulled from existing frozen inventory. DRL coordinates handling, processing, QC, and clinical metadata capture aligned to your study design. Samples are sourced fresh through our 33-hospital and 18-clinic network within 24 hours of surgery.

DRL provides fresh frozen tumor tissue, FFPE blocks and slides, blood products (PBMCs, plasma, serum), and selected biofluids across oncology and select non-oncology indications. Over 200 FFPE tumor samples are available across 30+ cancer types. Custom prospective collection is available for programs that need specific tissue not in current inventory.

Every sample goes through pre-distribution handling SOPs, viability and quality checks, and full chain-of-custody documentation from surgical procurement to client hands. IRB-approved sourcing and linked clinical metadata are standard — so your team can trust the data derived from DRL material at IND review.

Patient-derived tumor organoids (PDOs) are 3D cultures built directly from a real patient’s tumor tissue. Unlike PDX models that are passaged through animals — losing tumor heterogeneity and immune context in the process — DRL’s PDOs retain the cellular architecture, genetic diversity, and drug response behavior of the original tumor. The organoid market is growing at ~19% CAGR because the field is recognizing what human-derived 3D models can do that animal models cannot.

PDOs are well matched for drug response and resistance studies, combination therapy screening, TME/immune co-culture modeling, and biomarker discovery. They are particularly valuable for programs where PDX engraftment timelines (6–8 weeks) are incompatible with board milestones or IND-enabling schedules.

DRL generates primary 2D and 3D models in days to weeks from fresh tissue procurement — significantly faster than PDX engraftment, which requires 6–8 weeks before any assay can begin. Exact timelines depend on tumor type, study design, and required QC checkpoints. Our team will confirm lead times upfront based on your program.

Bio-Verify is DRL’s GLP-aligned research services platform. It includes drug screening and hit identification, functional assays (including immune profiling), molecular profiling and multi-omics (transcriptomics, mutational profiling), and biomarker discovery and validation. All studies are documented for IND-enabling workflows — not just internal decision-making.

Yes. Bio-Verify studies are run on DRL-derived primary human cell models and patient-derived organoids for consistency, traceability, and full chain-of-custody documentation. This ensures the biology in the assay reflects real patient tumors — and that your data holds up at IND. Alternative material can be discussed based on study requirements.